Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5

• Status: Withdrawn
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a proof-of-concept clinical study designed to test the hypothesis that oral administration of galactose can lower the level of a circulating factor that increases glomerular permeability to albumin in patients with resistant FSGS.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwell Health
• Collaborator: Medical College of Wisconsin

Criteria

Inclusion Criteria:

• Primary FSGS

• CKD Stage 5

• Resistance to steroids and another immunosuppressive medication

Exclusion Criteria:

• Secondary FSGS